We use cookies to help provide you with the best possible online experience. Learn more

Press releases

RayStation selected for new Netherlands proton therapy center

The South-East Netherlands Proton Therapy Centre (ZON-PTC), located in Maastricht, has selected RayStation as its treatment planning system following an extensive evaluation of the leading software systems. Scheduled to open by early 2019, the new center will have a single-room setup utilizing the MEVION S250i Proton Therapy System with HYPERSCAN technology.

Maria Jacobs, CEO of ZON-PTC and MAASTRO Clinic, says: “The initiative will enable patients in the Netherlands and beyond to benefit from this highly precise form of treatment. Our approach also demonstrates that technological innovation can be cost-effective. RayStation is an important aspect in this, combining advanced clinical functionality with an outstanding user experience to ensure smooth and efficient workflows.”

The RayStation configuration will include pencil beam scanning, deformable registration, dose tracking, contouring and the full module for adaptive therapy. ZON-PTC is a joint undertaking between MAASTRO clinic and the Maastricht University Medical Centre (Maastricht UMC+). The state-of-the-art facility will deliver the benefits of proton therapy to patients across the southeast region of the Netherlands and will also be a referral site for hospitals across the country. The center expects to treat up to 400 patients per year.

Geert Bosmans, Head of Clinical Proton Physics at ZON-PTC, says: “RayStation is the most advanced treatment planning system available and will give us wide-ranging clinical possibilities. ZON-PTC will be one of the first centers worldwide to combine RayStation and Mevion’s HYPERSCAN, and we look forward to collaborating on the implementation of all functionalities, including Adaptive Aperture. Fast calculation speed makes RayStation ideal when planning for complex cases, and it has the capabilities we need for efficient adaptive therapy, which is one of our priorities.

Johan Löf, CEO of RaySearch, says: “RaySearch has a strong focus on proton therapy and we have designed RayStation to meet the demands of pioneering centers such as ZON-PTC. I am very pleased to support this outstanding collaboration, which will help to improve quality of life for many cancer patients.”

The Southeast Netherlands Proton Therapy Center (ZON-PTC) is an initiative of MAASTRO Clinic and Maastricht UMC+. MAASTRO Clinic is a leading institute offering conventional radiation therapy with photons. Maastricht UMC+ is known both nationally and internationally for its focus on prevention and integrated approach to health care.
ZON-PTC will benefit from the knowledge and expertise of both institutions and will share existing facilities.

About RayStation
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

* Subject to regulatory clearance in some markets

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00